This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Prevo, R. Articles by Bernhard, E. J. Search for Related Content PubMed PubMed Citation Articles by Prevo, R. Articles by Bernhard, E. J.

Class I PI3 Kinase Inhibition by the Pyridinylfuranopyrimidine Inhibitor PI-103 Enhances Tumor Radiosensitivity

¹ Radiobiology Research Institute, Oxford University, Oxford, United Kingdom; ² Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France; ³ Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania; ⁴ MRC Radiation and Genome Stability Unit, Harwell, United Kingdom; and ⁵ Piramed Pharma, Slough, United Kingdom

Requests for reprints: Eric J. Bernhard, Oxford University, Radiation Oncology and Biology, Radiobiology Research Institute Building, Churchill Hospital Headington, Oxford OX3 7LJ, United Kingdom. Phone: 44-0-1865-225838; Fax: 44-0-1865-857127; E-mail: eric.bernhard{at}rob.ox.ac.uk.

Key Words: PI3 kinase • AKT • Radiation • H2AX • PI-103

Cell signaling initiated at the epidermal growth factor receptor (EGFR), RAS oncoproteins, or PI3K contributes to a common pathway that promotes tumor survival after radiation-induced DNA damage. Inhibition of signaling at the level of EGFR, RAS, and PI3K has been tested, but clinical applicability has been shown only at the level of the EGFR or by inhibiting RAS indirectly with prenyltransferase inhibitors. Inhibition of PI3K with LY294002 or wortmannin lacks specificity and has shown unacceptable toxicity in preclinical studies. We previously showed that inhibiting class I PI3K expression with siRNA resulted in enhanced radiation killing of tumor cells. Here, we tested the possibility of achieving specific tumor cell radiosensitization with a pharmacologic inhibitor of class I PI3K, the pyridinylfuranopyrimidine inhibitor PI-103. Our results show that inhibiting PI3K activity reduces phosphorylation of AKT at serine 473. Reduced survival is seen in cells with AKT activation and seems preferential for tumor cells over cells in which AKT activity is not elevated. Reduced survival is accompanied by persistence of DNA damage as evidenced by persistence of H2AX and Rad 51 foci after irradiation in the presence of the inhibitor. Reduced survival does not result from cell cycle redistribution during the PI-103 treatment intervals tested, although combining PI-103 treatment with radiation enhances the G₂-M delay observed after irradiation. These results indicate that pharmacologic inhibitors with enhanced specificity for class I PI3K may be of benefit when combined with radiotherapy. [Cancer Res 2008;68(14):5915–23]

This article has been cited by other articles:

				L. Krasny, N. Shimony, K. Tzukert, R. Gorodetsky, S. Lecht, D. M. Nettelbeck, and Y. S. Haviv An in-vitro tumour microenvironment model using adhesion to type I collagen reveals Akt-dependent radiation resistance in renal cancer cells Nephrol. Dial. Transplant., October 13, 2009; (2009) gfp525v1. [Abstract] [Full Text] [PDF]

				N. Qayum, R. J. Muschel, J. H. Im, L. Balathasan, C. J. Koch, S. Patel, W. G. McKenna, and E. J. Bernhard Tumor Vascular Changes Mediated by Inhibition of Oncogenic Signaling Cancer Res., August 1, 2009; 69(15): 6347 - 6354. [Abstract] [Full Text] [PDF]

				K.-T. Kuo, T.-L. Mao, S. Jones, E. Veras, A. Ayhan, T.-L. Wang, R. Glas, D. Slamon, V. E. Velculescu, R. J. Kuman, et al. Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma Am. J. Pathol., May 1, 2009; 174(5): 1597 - 1601. [Abstract] [Full Text] [PDF]